Cost-Effectiveness of the Absorbable Antibacterial Envelope for Infection Control in Cardiac Implantable Electronic Device Implantation in Spain

Author(s)

Pellicer Vercher B1, Alvarez Orozco M2, Eggington S3
1Medtronic Ibérica, S.A., Madrid, M, Spain, 2Medtronic Ibérica S.A., Madrid, Madrid, Spain, 3Medtronic International Trading Sarl, Tolochenaz, VD, Switzerland

OBJECTIVES: Infection is a serious complication of cardiac implantable electronic device (CIED) implantation that is difficult to diagnose and treat, usually associated with prolonged hospital stays, substantial morbidity, and death. Our aim is to model the cost-effectiveness of the Absorbable Antibacterial Envelope for infection prevention in patients undergoing a CIED implantation in the context of the Spanish healthcare system.

METHODS: A decision tree model with a lifetime horizon was populated to compare standard of care (SoC), consisting of one course of pre-operative antibiotic prophylaxis only, versus SoC plus the envelope in patients undergoing a CIED implantation. The model considers clinical inputs for infection (REINFORCE) and mortality rates (AdaptResponse, WRAP-IT) at 12-, 24- and 36-months post-implant; costs (€, 2023) from Spanish databases and benefits in quality-adjusted life-years (QALY) gained using the EQ-5D-5L data from WRAP-IT. The incremental cost-effectiveness ratio (ICER) is presented per device type and aggregated according to the current Spanish treatment mix [77% pacemaker (PM), 15% Implantable Cardiac Defibrillator (ICD), 5% Cardiac Resynchronization Therapy-Defibrillator (CRT-D), 3% Cardiac Resynchronization Therapy-Pacemaker (CRT-P)]. Probabilistic sensitivity analysis (PSA) was conducted to test the robustness of the analysis.

RESULTS: For CRT-D and ICD patients, the envelope is a dominant alternative, and cost-effective for PM (€18,160/QALY) and CRT-P (€14,627/QALY) when compared to the SoC considering a willingness to pay (WTP) threshold of €25.000/QALY. Averaging across all devices, the ICER was €10,798/QALY. PSA corroborates the base-case results as the envelope remained cost-effective for all-devices in 69%, 80%, 89% of model replications at €20,000/QALY, €30,000/QALY and €50,000/QALY WTP thresholds, respectively, compared with SoC.

CONCLUSIONS: The absorbable antibacterial envelope was associated with ICER values below the Spanish WTP regardless of the implanted CIED, suggesting the envelope provides value for the Spanish healthcare system by preventing CIED infections.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

EE371

Topic

Economic Evaluation, Health Technology Assessment, Medical Technologies

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Decision & Deliberative Processes, Medical Devices

Disease

Medical Devices

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×